https://www.selleckchem.com/products/ABT-888.html
(with more than 5 drugs) and chemotherapeutic (with more than 4 drugs) effects, thrombocytopenia and manifestation of delirium, as well as one risk factor a history of neurological disorder. These factors need to be considered and monitored during treatment, because each of them increases the risk of developing SLCNS. The main types of SLCNS in patients with HM were epileptic seizure, ischemic and hemorrhagic strokes, and meningoencephalitis. Four predictors associated with the development of SLCNS in the course of HM treatment were ide
Like
Comment
Share
